• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相对于淀粉样蛋白发病,血浆生物标志物、脑萎缩和认知衰退轨迹中的性别差异。

Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset.

作者信息

Joynes Cassandra M, Bilgel Murat, An Yang, Moghekar Abhay R, Ashton Nicholas J, Kac Przemysław R, Karikari Thomas K, Blennow Kaj, Zetterberg Henrik, Thambisetty Madhav, Ferrucci Luigi, Resnick Susan M, Walker Keenan A

机构信息

Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

出版信息

Alzheimers Dement. 2025 Jan;21(1):e14405. doi: 10.1002/alz.14405. Epub 2024 Nov 28.

DOI:10.1002/alz.14405
PMID:39609257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11775450/
Abstract

INTRODUCTION

The factors that influence the progression of Alzheimer's disease (AD) after individuals become amyloid-positive are poorly understood. This study examines how sex influences the longitudinal trajectories of plasma AD and neurodegenerative biomarkers in the years following a person's estimated onset of amyloid-β.

METHODS

Linear mixed-effects modeling investigated overall and sex-specific longitudinal trajectories of plasma biomarkers, brain volumes, and cognition relative to the estimated age of amyloid onset in a cohort of 78 amyloid-positive Baltimore Longitudinal Study of Aging (BLSA) participants (n = 45 male; follow-up time: 6.8 years [SD 3.31]). Amyloid status was ascertained with C-Pittsburgh compound B (PiB) PET imaging.

RESULTS

After amyloid onset, men displayed steeper increases in pTau181, pTau231, and neurofilament light (NfL) compared to women. In this same period, men demonstrated steeper declines in brain volume and cognitive performance.

DISCUSSION

These findings suggest that sex influences the trajectory of AD pathology, neuronal injury, and symptom progression after individuals become amyloid-positive.

HIGHLIGHTS

Steeper rates of increase in pTau and GFAP among amyloid-positive individuals. After amyloid onset, steeper increases in pTau and NfL concentrations in men than in women. Steeper declines in brain volume and cognition in men corroborate biomarker results.

摘要

引言

个体出现淀粉样蛋白阳性后,影响阿尔茨海默病(AD)进展的因素尚不清楚。本研究探讨了性别如何影响个体估计出现淀粉样β蛋白后的几年中血浆AD和神经退行性生物标志物的纵向轨迹。

方法

采用线性混合效应模型,研究了78名淀粉样蛋白阳性的巴尔的摩纵向衰老研究(BLSA)参与者队列(n = 45名男性;随访时间:6.8年[标准差3.31])中,血浆生物标志物、脑容量和认知相对于估计淀粉样蛋白发病年龄的总体和性别特异性纵向轨迹。淀粉样蛋白状态通过C-匹兹堡化合物B(PiB)PET成像确定。

结果

淀粉样蛋白发病后,与女性相比,男性的pTau181、pTau231和神经丝轻链(NfL)升高更为明显。在同一时期,男性的脑容量和认知能力下降更为明显。

讨论

这些发现表明,性别会影响个体出现淀粉样蛋白阳性后的AD病理、神经元损伤和症状进展轨迹。

重点

淀粉样蛋白阳性个体中pTau和GFAP的升高速度更快。淀粉样蛋白发病后,男性的pTau和NfL浓度升高比女性更明显。男性脑容量和认知能力的下降更明显,这证实了生物标志物的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/7130afd97768/ALZ-21-e14405-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/c736bff17ce3/ALZ-21-e14405-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/6f9ae514140b/ALZ-21-e14405-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/e4237093cf57/ALZ-21-e14405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/13246b6bf569/ALZ-21-e14405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/2ac827018755/ALZ-21-e14405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/41d826d8b1e8/ALZ-21-e14405-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/7130afd97768/ALZ-21-e14405-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/c736bff17ce3/ALZ-21-e14405-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/6f9ae514140b/ALZ-21-e14405-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/e4237093cf57/ALZ-21-e14405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/13246b6bf569/ALZ-21-e14405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/2ac827018755/ALZ-21-e14405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/41d826d8b1e8/ALZ-21-e14405-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb8/11775450/7130afd97768/ALZ-21-e14405-g006.jpg

相似文献

1
Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset.相对于淀粉样蛋白发病,血浆生物标志物、脑萎缩和认知衰退轨迹中的性别差异。
Alzheimers Dement. 2025 Jan;21(1):e14405. doi: 10.1002/alz.14405. Epub 2024 Nov 28.
2
Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.血液中的阿尔茨海默病和神经退行性疾病生物标志物可预测脑萎缩和认知能力下降。
Alzheimers Res Ther. 2024 Apr 30;16(1):94. doi: 10.1186/s13195-024-01459-y.
3
Association of Plasma Biomarkers of Alzheimer Disease and Neurodegeneration With Longitudinal Intra-Network Functional Brain Connectivity.阿尔茨海默病和神经退行性变的血浆生物标志物与纵向脑内网络功能连接的关联
Neurology. 2025 Feb 25;104(4):e210271. doi: 10.1212/WNL.0000000000210271. Epub 2025 Jan 31.
4
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau蛋白脑沉积及认知衰退:一项纵向队列研究。
Lancet Neurol. 2025 Jul;24(7):591-600. doi: 10.1016/S1474-4422(25)00158-9.
5
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.肾功能对阿尔茨海默病血液生物标志物的影响:对预测淀粉样蛋白-β阳性的意义。
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
6
Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.血浆淀粉样蛋白、P-tau、GFAP 和 NfL 与路易体痴呆患者脑脊液、临床和认知特征的关联。
Neurology. 2024 Jun 25;102(12):e209418. doi: 10.1212/WNL.0000000000209418. Epub 2024 Jun 3.
7
Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration.淀粉样蛋白和心脏代谢危险因素对神经退行性病变患者血浆神经丝轻链的预后能力的影响。
Alzheimers Res Ther. 2024 Sep 12;16(1):202. doi: 10.1186/s13195-024-01564-y.
8
Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.血浆生物标志物与神经退行性疾病和脑血管疾病患者MRI上纵向萎缩及微血管负荷的关联
Neurology. 2025 Apr 8;104(7):e213438. doi: 10.1212/WNL.0000000000213438. Epub 2025 Mar 10.
9
Sex differences in the association of Alzheimer's disease biomarkers and cognition in a multicenter memory clinic study.一项多中心记忆门诊研究中阿尔茨海默病生物标志物与认知关联的性别差异
Alzheimers Res Ther. 2025 Feb 18;17(1):46. doi: 10.1186/s13195-025-01684-z.
10
Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinics.理清三级记忆诊所患者中阿尔茨海默病血浆生物标志物与既定生物标志物之间的关系。
EBioMedicine. 2025 Feb;112:105504. doi: 10.1016/j.ebiom.2024.105504. Epub 2024 Dec 18.

引用本文的文献

1
Age-related amyloid beta dynamics modeled with the generalized additive model for location, scale, and shape (GAMLSS) across diverse populations: Cross-sectional trajectories and longitudinal validation.使用位置、尺度和形状广义相加模型(GAMLSS)对不同人群中与年龄相关的淀粉样β动力学进行建模:横断面轨迹和纵向验证。
Alzheimers Dement. 2025 Sep;21(9):e70675. doi: 10.1002/alz.70675.
2
Physical activity and blood-based biomarkers of neurodegeneration in community dwelling Australians from ISLAND (Island Study Linking Ageing and Neurodegenerative Disease).来自ISLAND(衰老与神经退行性疾病关联岛屿研究)的澳大利亚社区居民的身体活动与基于血液的神经退行性变生物标志物
Alzheimers Dement (Amst). 2025 Aug 17;17(3):e70166. doi: 10.1002/dad2.70166. eCollection 2025 Jul-Sep.
3

本文引用的文献

1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
2
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease.星形胶质细胞反应影响了淀粉样蛋白-β对临床前阿尔茨海默病中 tau 病理的影响。
Nat Med. 2023 Jul;29(7):1775-1781. doi: 10.1038/s41591-023-02380-x. Epub 2023 May 29.
3
Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers.
Local cerebral neurofilament light chain during acute stage is associated with clinical outcomes in stroke patients receiving endovascular thrombectomy.急性卒中患者接受血管内血栓切除术时,局部脑神经元细丝轻链水平与临床预后相关。
BMC Neurol. 2025 Jul 10;25(1):285. doi: 10.1186/s12883-025-04290-6.
没有证据表明脑血管病与阿尔茨海默病影像学生物标志物之间存在时间关联。
Nat Commun. 2023 May 29;14(1):3097. doi: 10.1038/s41467-023-38878-8.
4
Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.阿尔茨海默病相关血浆生物标志物和脑淀粉样蛋白的纵向变化。
Alzheimers Dement. 2023 Oct;19(10):4335-4345. doi: 10.1002/alz.13157. Epub 2023 May 22.
5
Predicting amyloid PET and tau PET stages with plasma biomarkers.用血浆生物标志物预测淀粉样蛋白 PET 和 tau PET 分期。
Brain. 2023 May 2;146(5):2029-2044. doi: 10.1093/brain/awad042.
6
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.使用血浆生物标志物预测临床前阿尔茨海默病的纵向认知下降。
JAMA Neurol. 2023 Apr 1;80(4):360-369. doi: 10.1001/jamaneurol.2022.5272.
7
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
8
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.早期症状性阿尔茨海默病中 Donanemab 治疗与探索性血浆生物标志物的关联:TRAILBLAZER-ALZ 随机临床试验的二次分析。
JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.
9
Causal links among amyloid, tau, and neurodegeneration.淀粉样蛋白、tau蛋白与神经退行性变之间的因果联系。
Brain Commun. 2022 Jul 25;4(4):fcac193. doi: 10.1093/braincomms/fcac193. eCollection 2022.
10
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.多方法研究三个队列中影响淀粉样蛋白发病和损伤的因素。
Brain. 2022 Nov 21;145(11):4065-4079. doi: 10.1093/brain/awac213.